Publications by authors named "D G Costagliola"
Harmonization of alcohol use data and mortality across a multi-national HIV cohort collaboration.
Alcohol Clin Exp Res (Hoboken)
January 2025
Background: Alcohol use is measured in diverse ways across settings. Harmonization of measures is necessary to assess effects of alcohol use in multi-cohort collaborations, such as studies of people with HIV (PWH).
Methods: Data were combined from 14 HIV cohort studies (nine European, five North American) participating in the Antiretroviral Therapy Cohort Collaboration.
Background: The Bari-SolidAct randomized controlled trial compared baricitinib with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher incidence of serious adverse events (SAEs) among SARS-CoV-2-vaccinated participants who had received baricitinib. This sub-study aimed to investigate whether vaccination influences the safety profile of baricitinib in patients with severe COVID-19.
View Article and Find Full Text PDFArticle Synopsis
- HIV infection increases the risk of diffuse large B-cell lymphoma (DLBCL), and this study analyzed B-cell activating cytokines and T cell subsets in 51 HIV-associated DLBCL patients undergoing R-CHOP treatment.
- R-CHOP therapy led to decreased IL-10 and fluctuating IL-6 levels while BAFF levels initially rose and then fell; a significant increase in naïve B cells was observed, but recovery of other B cell types was gradual.
- With a median follow-up of 41 months, 5-year progression-free survival was 61.8% and overall survival was 67.4%, with main causes of death being disease progression and sepsis, highlighting the need for assessing B-cell disturbances in patient
Article Synopsis
- Mpox, a disease first reported in France in May 2022, led to a recommendation for live Modified Vaccinia Ankara (MVA-BN) vaccination for multiple-partner men who have sex with men (MSM) starting July 11, 2022.
- A study analyzed the changes in sexual behaviors of MSM on HIV pre-exposure prophylaxis (PrEP) and assessed the effects of vaccination on mpox incidence, revealing significant behavioral shifts and a substantial decrease in infection rates post-vaccination.
- The results showed a notable drop in mpox incidence from 67.4 to 24.4 cases per 1000 person-months after the vaccination roll-out, indicating a 99% risk reduction
Background: Understanding the reasons for and consequences of bodyweight change in people living with HIV initiating antiretroviral therapy (ART) is crucial to optimising long-term health and wellbeing. We aimed to examine bodyweight trends and associated factors among individuals with well estimated dates of HIV-1 seroconversion.
Methods: In this cohort study, we pooled retrospective data from clinical records of participants in CASCADE aged 16 years and older recruited from clinics in France, Greece, the Netherlands, Spain, Sweden, the UK, and Canada.